Norfenfluramine
From Wikipedia, the free encyclopedia
| Norfenfluramine | |
|---|---|
 |
|
|
1-[3-(Trifluoromethyl)phenyl]propan-2-amine |
|
|
Other names
3-Trifluoromethylamphetamine |
|
| Identifiers | |
| CAS number | 19036-73-8  |
| PubChem | 15897 |
| ChemSpider | 15108 |
| IUPHAR ligand | 215 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C10H12F3N |
| Molar mass | 203.2 g mol−1 |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references |
Norfenfluramine (3-trifluoromethylamphetamine) is a psychoactive drug which functions as a serotonin releasing agent and potent 5HT2B receptor agonist. The action of norfenfluramine on 5HT2B receptors on heart valves leads to a characteristic pattern of heart failure following proliferation of cardiac fibroblasts on the tricuspid valve, known as cardiac fibrosis.[1] This side effect led to the withdrawal of fenfluramine as an anorectic drug worldwide, and to the withdrawal of benfluorex in Europe[2], as both fenfluramine and benfluorex form norfenfluramine as a metabolite.
Norfenfluramine has also been shown to be vasoactive in its own right, causing pulmonary hypertension.[3][4]
[edit] See also
- 3-Fluoroamphetamine
- 3-Methylamphetamine
- 3-Methoxyamphetamine
- Substituted amphetamine
- Gepefrine
- Desmethylcitalopram
- Desmethylsertraline
- Norfluoxetine
[edit] References
- ^ Setola, V; Dukat, M; Glennon, RA; Roth, BL (2005). "Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor". Molecular pharmacology 68 (1): 20–33. doi:10.1124/mol.104.009266. PMID 15831837.
- ^ Press Release European Medicines Agency recommends withdrawal of benfluorex from the market in European Union [1]
- ^ Hong, Z; Olschewski, A; Reeve, HL; Nelson, DP; Hong, F; Weir, EK (2004). "Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine". American journal of physiology. Lung cellular and molecular physiology 286 (3): L531–8. doi:10.1152/ajplung.00247.2003. PMID 14607779.
- ^ Ni, W; Li, MW; Thakali, K; Fink, GD; Watts, SW (2004). "The fenfluramine metabolite (+)-norfenfluramine is vasoactive". The Journal of pharmacology and experimental therapeutics 309 (2): 845–52. doi:10.1124/jpet.103.060806. PMID 14752059.
|
|
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
